Novartis Bioventures Ltd
CIK 1297709 · last filed 2020-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WSJ-200.220
CH-4002 BASEL, V8 0000000000
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Galera Therapeutics, Inc. (GRTX) Delisted | 10%+ Owner | 35,061 | $17.60 | $617.1K | -$11.18M | 4 | 2020-06-22 |
| BCYC | 10%+ Owner | 1,769,641 | $3.56 | $6.30M | $4.72M | 1 | 2019-05-30 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | 10%+ Owner | 279,234 | $33.00 | $9.21M | -$2.89M | 6 | 2019-04-29 |
| Rein Therapeutics, Inc. (ALRN) Delisted | 10%+ Owner | 105,000 | $2.11 | $221.6K | -$1.69M | 9 | 2019-04-02 |
| ALT | 10%+ Owner | 8,345,145 | $2.17 | $18.07M | $0 | 8 | 2018-09-14 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 87,013 | $12.01 | $1.05M | -$2.74M | 3 | 2018-05-14 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 2,254,677 | — | — | -$12.06M | 7 | 2017-06-20 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | 10%+ Owner | 499,273 | — | — | -$133.7K | 2 | 2015-07-17 |
| AKBA | 10%+ Owner | 182,590 | $0.55 | $100.9K | $3.10M | 1 | 2014-03-27 |
| Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | 10%+ Owner | 103,448 | — | — | $1.30M | 1 | 2014-02-06 |
| Adhera Therapeutics, Inc. (MRNAD) Delisted | 10%+ Owner | 2,560,565 | — | — | -$383.4K | 1 | 2011-01-27 |
Recent Filings · Page 5 of 5
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-18 | Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Sell (S) | −2,240 | -$32.0K | EDGAR |
| 2014-03-27 | AKBA | Mixed | +3,405,764 | $3.10M | EDGAR |
| 2014-02-06 | Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | Mixed | +1,551,721 | $1.43M | EDGAR |
| 2011-01-27 | Adhera Therapeutics, Inc. (MRNAD) Delisted | Sell (S) | −335,010 | -$383.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.